SEC Form 4 · accession 0001628280-26-044083
Arcutis Biotherapeutics, Inc. · ARQT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sue-Jean Lin
Director
Period of report
Jun 15, 2026
Accepted (ET)
Jun 17, 2026 · 8:47 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001787306
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 15, 2026 | S | 4,946 | $24.3807 | D | 27,567 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on December 4, 2025, by the Reporting Person, with a plan end date of February 19, 2027.
- F2The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.045 to $24.62, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.